Related Experiment Video

Updated: Nov 26, 2025

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.8K

Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues

Anoop Mohamed Iqbal1, Nasvin Imamudeen2, Amjad Basheer3

  • 11Division of Pediatric Endocrinology, Marshfield Medical Center, 1000 N oak ave, Wisconsin, United States.

Current Drug Safety
|December 9, 2020
PubMed

Insights

Glucagon-like peptide-1 receptor analogs (GLP-1RAs) offer glycemic control and potential vascular benefits for type 2 diabetes. Some GLP-1RAs show cardiovascular event reduction, while others have neutral results, necessitating individualized treatment decisions.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor analogs (GLP-1RAs) are incretin mimetics used for type 2 diabetes mellitus (T2DM) management.
  • These agents demonstrate glucose-dependent insulin secretion, potential pancreatic beta-cell benefits, weight loss, and vascular effects.
  • Semaglutide, a newer GLP-1RA, shows significant HbA1c reduction, but differences exist among agents regarding efficacy and cardiovascular protection.

Purpose of the Study:

  • To review randomized controlled trials (RCTs) evaluating the cardiovascular effects of various GLP-1RAs.
  • To compare the individual cardiovascular benefits and outcomes of different GLP-1RAs.
  • To summarize generalizable aspects of GLP-1RAs for clinical practice.

Main Methods:

  • Systematic review of published cardiovascular outcome trials (CVOTs) for six GLP-1RAs: lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6), exenatide (EXSCEL), dulaglutide (REWIND), and oral semaglutide (PIONEER 6).
  • Analysis of trial follow-up durations ranging from 2 to 4 years.
  • Comparison of efficacy, pharmacokinetics, tolerability, and vascular protection data.

Main Results:

  • Three major CVOTs (LEADER, REWIND, SUSTAIN-6) demonstrated a significant reduction in major adverse cardiovascular events (MACE) with GLP-1RA treatment.
  • Three other CVOTs (ELIXA, PIONEER 6, EXSCEL) reported neutral findings regarding MACE.
  • Individual GLP-1RAs exhibit variability in their cardiovascular protective effects.

Conclusions:

  • GLP-1RAs represent a significant advancement in T2DM management, offering both glycemic control and potential cardiovascular benefits.
  • The differential cardiovascular outcomes among GLP-1RAs underscore the importance of personalized treatment strategies.
  • Further research and clinical evaluation are essential to fully elucidate the role of specific GLP-1RAs in cardiovascular risk reduction for T2DM patients.
Keywords:
Diabetes mellituscardiovascular diseasecardiovascular outcome trials (CVOTs)glucagon-Like peptide 1semaglutideweight- loss

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

458

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
622
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
382
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
436
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
410
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
473
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
551